How will Torrent Pharma benefit from the acquisition of JB Chemicals?

Synopsis: Torrent Pharma’s acquisition of JB Chemicals will raise its domestic market rank from 7th to 5th, with Rs. 12,500 cr raised via bonds and Rs. 1,500 cr via commercial paper, enhancing scale, synergies, and competitiveness.

One of the leading Indian pharmaceutical companies engaged in research, development, manufacturing, and marketing of generic pharmaceutical formulations is now in the spotlight following the news of the acquisition of JB Chemicals & Pharmaceuticals by raising bonds and commercial paper.

With a market capitalisation of Rs. 1,33,477 cr, the shares of Torrent Pharmaceuticals Ltd are currently trading at Rs. 3,944 per share, up from its previous close of Rs. 3,939.55 per share.

With a market capitalisation of Rs. 29,199 cr, the shares of JB Chemicals & Pharmaceuticals Ltd are currently trading at Rs. 1,864 per share, down from its previous close of Rs. 1,867.50 per share.

Torrent Pharmaceuticals Ltd’s acquisition of JB Chemicals & Pharmaceuticals is set to significantly strengthen its position in India’s pharmaceutical market. post-acquisition, Torrent Pharma is expected to move up from 7th to 5th in domestic market share, enhancing its competitive standing and scale in key therapeutic areas. This rise in ranking will give the company better visibility and reach among distributors, healthcare professionals, and patients.

Financially, the acquisition will be funded through India’s domestic debt market, with Torrent raising Rs. 12,500 crore via short-term bonds (1–5 year maturities) and Rs. 1,500 crore via commercial paper. Rated AA+ by India Ratings, this is set to be one of the largest fundraising exercises of FY2026, highlighting the company’s ability to leverage domestic financial markets for strategic growth.

Beyond scale and funding, the merger is expected to create operational synergies through shared manufacturing, distribution, and marketing networks, leading to potential cost efficiencies and improved margins. Overall, the acquisition positions Torrent Pharma for long-term growth, stronger domestic presence, and enhanced competitiveness both in India and abroad.

Torrent Pharma has agreed to acquire a controlling ~49.2 percent stake in JB Chemicals & Pharmaceuticals (about 46.39 percent from KKR plus ~2.8 percent from employees) and has also announced an open offer to buy up to an additional 26 percent from public shareholders. The deal has received key approvals such as from the CCI, but the open offer and final merger approvals are still pending, so the acquisition is not yet fully complete. If the open offer is fully accepted, Torrent’s total holding could rise to around 75 percent.

About the Companies

Torrent Pharmaceuticals is the flagship company of the Torrent Group, is a leading Indian pharma firm. It is a pioneer in niche marketing and a leader in cardiovascular, CNS, gastro-intestinal, women’s healthcare, and cosmo-dermatology segments, with a presence in diabetology, oncology, pain management, and anti-infectives.

Sales of the company grew from Rs. 3,178 cr in Q1FY26 to Rs. 3,302 cr in Q2FY26.  Operating profit increased to Rs. 1,083 cr from Rs. 1,032 cr. Net profit rose from Rs. 548 cr to Rs. 591 cr over the same period.

J B Chemicals & Pharmaceuticals Ltd is a well‑established Indian pharmaceutical company that develops, manufactures, and markets a wide range of formulations, APIs, and herbal remedies for domestic and international markets. It has a diverse product portfolio covering tablets, injectables, syrups, and serves over 40 countries with both generics and branded products

Sales of the company fell from Rs. 1,094 cr in Q1FY26 to Rs. 1,085 cr in Q2FY26.  Operating profit increased to Rs. 310 cr from Rs. 301 cr. Net profit rose from Rs. 202 cr to Rs. 208 cr over the same period.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post How will Torrent Pharma benefit from the acquisition of JB Chemicals? appeared first on Trade Brains.